Arecor Therapeutics PLC (AIM:AREC), the biopharma group focused on diabetes, said it has been granted a patent from the United States Patent and Trademark Office.
The patent (US11608357) protects a formulation platform for developing enhanced monoclonal antibodies.
Monoclonal antibodies represent a crucial segment in the pharma market, valued at US$210bn in 2022, with an expected compound annual growth rate of 11.04% from 2023 to 2030.
Arecor's proprietary formulation platforms address stability issues often found in conventional approaches. The US patent protects one of these platforms within the company's Arestat technology. The granted patent strengthens Arecor's extensive patent portfolio.
Dr Jan Jezek, the company's chief scientific officer, said: "Monoclonal antibodies continue to dominate the biopharmaceutical field.
"Safety and efficacy are the key criteria for any new product, but the increasing focus on patient-centricity and improved convenience of delivery often require superior product stability.
"Our highly innovative formulation technology addresses these challenges and allows us to develop enhanced novel pharmaceutical products.
"This US patent is a very important addition to our IP portfolio, protecting a formulation design space that enables monoclonal antibodies with superior stability."